Malignancy Clinical Trials

19 recruiting

Malignancy Trials at a Glance

175 actively recruiting trials for malignancy are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 54 trials, with the heaviest enrollment activity in Boston, Philadelphia, and Hangzhou. Lead sponsors running malignancy studies include Cancer Research UK, St. Jude Children's Research Hospital, and Massachusetts General Hospital.

Browse malignancy trials by phase

Treatments under study

About Malignancy Clinical Trials

Looking for clinical trials for Malignancy? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignancy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 175 trials

Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1Phase 2

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI)31 enrolled1 locationNCT04645160
Recruiting
Phase 1Phase 2

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1Phase 2

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Acute Myeloid LeukemiaMyeloid Malignancy
Benjamin Tomlinson20 enrolled2 locationsNCT06129734
Recruiting
Not Applicable

Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment

Hematologic Malignancy
Duke University60 enrolled1 locationNCT06532773
Recruiting
Not Applicable

Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation

Hematologic MalignancyHematopoietic Cell Transplant
Massachusetts General Hospital40 enrolled1 locationNCT06676852
Recruiting
Not Applicable

Germline Testing for Predisposition to Myeloid Malignancies

Genetic Predisposition to DiseaseMyeloid MalignancyMyeloid Hematological Malignancies
Christopher Reilly200 enrolled1 locationNCT07112287
Recruiting
Not Applicable

Allergy Delabeling in Antibiotic Stewardship - Intervention

Hematologic MalignancyBeta Lactam Allergy
Ebbing Lautenbach3,800 enrolled1 locationNCT07133074
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 2

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical CancerRecurrent Cervical CarcinomaHPV-Related Malignancy+2 more
Precigen, Inc24 enrolled3 locationsNCT06157151
Recruiting
Not Applicable

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Multiple MyelomaLymphomaLeukemia+2 more
Massachusetts General Hospital90 enrolled1 locationNCT05646576
Recruiting

Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Hematologic Malignancy
Northside Hospital, Inc.20 enrolled1 locationNCT05417971
Recruiting
Phase 1Phase 2

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 2

GM-CSF With Post-Transplant Cyclophosphamide

Transplant-Related Hematologic Malignancy
Northside Hospital, Inc.38 enrolled1 locationNCT04237623
Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1Phase 2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

Haematological MalignancyBlood CancerFungal Infection+1 more
The University of Queensland104 enrolled7 locationsNCT06510699
Recruiting
Phase 2

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

NeutropeniaHematological Malignancy
West Virginia University55 enrolled1 locationNCT05537896
Recruiting
Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Hematologic MalignancyRelapsed Pediatric ALLHematopoietic Cell Transplantation
St. Jude Children's Research Hospital60 enrolled1 locationNCT07257419
Recruiting
Phase 2

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

HPV-Related MalignancyHPV-Related CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
Memorial Sloan Kettering Cancer Center30 enrolled8 locationsNCT05307939